Literature DB >> 27913551

What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?

Tzu-Fei Wang1, Wendy Lim2.   

Abstract

A 35-year-old man presents with an acute unprovoked deep vein thrombosis of the left lower extremity. He is treated with anticoagulation and elects to discontinue treatment after 6 months. He subsequently develops polyarthralgias, fatigue, and a malar rash, and a diagnosis of systemic lupus erythematosus is made based on laboratory and clinical findings. Additional laboratory testing reveals persistent triple positive antiphospholipid antibodies, including lupus anticoagulant, high titer anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies. The patient is reinitiated on anticoagulation, and the patient's rheumatologist inquires if the addition of hydroxychloroquine could help to prevent recurrent thrombosis.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27913551      PMCID： PMC6142483          DOI： 10.1182/asheducation-2016.1.714

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  21 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients.

Authors:  A Schmidt-Tanguy; J Voswinkel; D Henrion; J F Subra; L Loufrani; V Rohmer; N Ifrah; C Belizna
Journal:  J Thromb Haemost       Date:  2013-10       Impact factor: 5.824

3.  Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups.

Authors:  Chi Chiu Mok; Sandy Shuk Kuen Tang; Chi Hung To; Michelle Petri
Journal:  Arthritis Rheum       Date:  2005-09

4.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

Review 5.  Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.

Authors:  Laurent Arnaud; Alexis Mathian; Hervé Devilliers; Amelia Ruffatti; Maria Tektonidou; Ricardo Forastiero; Vittorio Pengo; Marc Lambert; Guillaume Lefevre; Maria Angeles Martinez-Zamora; Juan Balasch; Denis Wahl; Zahir Amoura
Journal:  Autoimmun Rev       Date:  2014-10-22       Impact factor: 9.754

6.  Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.

Authors:  K T Ho; C W Ahn; G S Alarcón; B A Baethge; F K Tan; J Roseman; H M Bastian; B J Fessler; G McGwin; L M Vilá; J Calvo-Alén; J D Reveille
Journal:  Rheumatology (Oxford)       Date:  2005-07-19       Impact factor: 7.580

Review 7.  ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?

Authors:  Ara Metjian; Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 8.  The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

Authors:  D J Wallace; M Linker-Israeli; A L Metzger; V J Stecher
Journal:  Lupus       Date:  1993-02       Impact factor: 2.911

9.  A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

Authors:  D Erkan; Y Yazici; M G Peterson; L Sammaritano; M D Lockshin
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

10.  Thrombosis in systemic lupus erythematosus: a review article.

Authors:  Ibrahim A Al-Homood
Journal:  ISRN Rheumatol       Date:  2012-07-30
View more
  10 in total

Review 1.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27

2.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  mSystems       Date:  2021-11-02       Impact factor: 6.496

3.  The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus.

Authors:  Marcus Kai Xuan Tan; Thurston Yan Jia Heng; Anselm Mak
Journal:  Cells       Date:  2019-04-06       Impact factor: 6.600

4.  Acute aortoiliac occlusion in a patient with novel coronavirus disease-2019.

Authors:  Iris Naudin; Anne Long; Christophe Michel; Bertrand Devigne; Antoine Millon; Nellie Della-Schiava
Journal:  J Vasc Surg       Date:  2020-10-17       Impact factor: 4.268

Review 5.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01

Review 6.  Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.

Authors:  Siya Kamat; Madhuree Kumari
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

7.  Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?

Authors:  Christian A Devaux; Laurence Camoin-Jau; Jean-Louis Mege; Didier Raoult
Journal:  J Microbiol Immunol Infect       Date:  2021-01-05       Impact factor: 4.399

Review 8.  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?

Authors:  Beata Franczyk; Jacek Rysz; Jarosław Miłoński; Tomasz Konecki; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13

Review 9.  Pharmacotherapeutics of SARS-CoV-2 Infections.

Authors:  Bhavesh D Kevadiya; Jatin Machhi; Jonathan Herskovitz; Maxim D Oleynikov; Wilson R Blomberg; Neha Bajwa; Dhruvkumar Soni; Srijanee Das; Mahmudul Hasan; Milankumar Patel; Ahmed M Senan; Santhi Gorantla; JoEllyn McMillan; Benson Edagwa; Robert Eisenberg; Channabasavaiah B Gurumurthy; St Patrick M Reid; Chamindie Punyadeera; Linda Chang; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2021-01-06       Impact factor: 7.285

10.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Yanjun Qi; Yuchen Sun; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ronan Lordan; Ashwin N Skelly; Bharath Ramsundar; Christian Brueffer; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  ArXiv       Date:  2021-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.